Current Projects (PI Thomas Mindt)

• Novel homo- and heteromeric conjugates for tumor targeting (Institute project, 4 years starting September 2025)
• Development of protein-based radiopharmaceuticals (Industry project, starting August 2025)
• Development of novel chelators for emerging new radiometals (OeAD, ASEA-UNINET, 3 years starting March 2025)
• Metabolically stabilized Peptidomimetics for improved tumor targeting (Institute project, 4 years starting April 2024)
• Improved Nuclear Imaging by Pretargeting with Small Molecule (FWF, 14.08.2023 - 13.08.2027
• New applications for radiotherapy in nuclear medicine (Industry project, starting July 2023)
• Bi-Metallic Complexes for Synergistic & Theranostic Applicatios (FWF, 01.08.2022 - 31.07.2026)
• Markers for the activity of albumin-targeted platinum drugs (FWF, 01.08.2020 - 28.02.2025)

Former Projects (PI Thomas Mindt)

• Radiostar: Novel Chelators for Radio-Lanthanides and-Actinides (FFG Bridge-1, 2020-2023)
• Improved Tumour Targeting with Radiolabelled Peptido-mimetics (FWF, 2018-2023)